{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:26:40Z","timestamp":1783726000524,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01611-y","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:50:55Z","timestamp":1766587855000},"page":"1241-1253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delgocitinib Cream Reduces Itch and Pain in Moderate to Severe Chronic Hand Eczema: Phase\u00a03 DELTA\u00a01 and 2 Pooled Analyses"],"prefix":"10.1007","volume":"16","author":[{"given":"Andrea","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Schuttelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Baranowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Plohberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"2","key":"1611_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","volume":"37","author":"L Grant","year":"2020","unstructured":"Grant L, Seiding Larsen L, Burrows K, et al. Development of a conceptual model of Chronic Hand Eczema (CHE) based on qualitative interviews with patients and expert dermatologists. Adv Ther. 2020;37(2):692\u2013706.","journal-title":"Adv Ther"},{"issue":"11","key":"1611_CR2","first-page":"19","volume":"8","author":"D Dibenedetti","year":"2015","unstructured":"Dibenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe Chronic Hand Eczema. J Clin Aesthet Dermatol. 2015;8(11):19\u201327.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"13","key":"1611_CR3","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.3390\/jcm12134198","volume":"12","author":"A Zalewski","year":"2023","unstructured":"Zalewski A, Krajewski PK, Szepietowski JC. Prevalence and characteristics of itch and pain in patients suffering from Chronic Hand Eczema. J Clin Med. 2023;12(13):4198.","journal-title":"J Clin Med"},{"issue":"2","key":"1611_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2133.2009.09099.x","volume":"161","author":"C Moberg","year":"2009","unstructured":"Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. Br J Dermatol. 2009;161(2):397\u2013403.","journal-title":"Br J Dermatol"},{"key":"1611_CR5","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2147\/TCRM.S292504","volume":"16","author":"C Dubin","year":"2020","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of Chronic Hand Eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319\u201332.","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"1611_CR6","doi-asserted-by":"publisher","first-page":"e12840","DOI":"10.1111\/dth.12840","volume":"32","author":"GR Lee","year":"2019","unstructured":"Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840.","journal-title":"Dermatol Ther"},{"key":"1611_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2023.11.004","volume":"14","author":"A Egeberg","year":"2024","unstructured":"Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in Chronic Hand Eczema\u2014findings from the Danish Skin Cohort. JAAD Int. 2024;14:77\u201383.","journal-title":"JAAD Int"},{"issue":"3","key":"1611_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/cod.14020","volume":"86","author":"MM Sloot","year":"2022","unstructured":"Sloot MM, Loman L, Romeijn GLE, Rosenberg FM, Arents BWM, Schuttelaar MLA. Patients\u2019 perspectives on quality of care for Chronic Hand Eczema: a qualitative study. Contact Dermat. 2022;86(3):204\u201312.","journal-title":"Contact Dermat"},{"issue":"7","key":"1611_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jdv.19055","volume":"37","author":"H Ronsch","year":"2023","unstructured":"Ronsch H, Schiffers F, Ofenloch R, et al. Chronic Hand Eczema in Europe: patient experiences and perspectives (CHEPEP) in qualitative interviews. J Eur Acad Dermatol Venereol. 2023;37(7):1396\u2013405.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10470","key":"1611_CR10","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(24)01810-5","volume":"404","author":"S Weidinger","year":"2024","unstructured":"Weidinger S, Novak N. Hand eczema. Lancet. 2024;404(10470):2476\u201386.","journal-title":"Lancet"},{"issue":"4","key":"1611_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1600-0536.2007.01305.x","volume":"58","author":"A Lerbaek","year":"2008","unstructured":"Lerbaek A, Kyvik KO, Ravn H, Menne T, Agner T. Clinical characteristics and consequences of hand eczema\u2014an 8-year follow-up study of a population-based twin cohort. Contact Dermat. 2008;58(4):210\u20136.","journal-title":"Contact Dermat"},{"issue":"5","key":"1611_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/cod.14035","volume":"86","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermat. 2022;86(5):357\u201378.","journal-title":"Contact Dermat"},{"issue":"1","key":"1611_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/cod.14303","volume":"89","author":"A Bauer","year":"2023","unstructured":"Bauer A, Thyssen JP, Buhl T, et al. Treatment with delgocitinib cream improves itch, pain and other signs and symptoms of Chronic Hand Eczema: results from the Hand Eczema Symptom Diary in a phase\u00a0IIb randomized clinical trial. Contact Dermat. 2023;89(1):46\u201353.","journal-title":"Contact Dermat"},{"issue":"4","key":"1611_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00403-024-02818-3","volume":"316","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Agner T, Baranowski K, et al. Validation of the Investigator Global Assessment of Chronic Hand Eczema (IGA-CHE): a new clinician reported outcome measure of CHE severity. Arch Dermatol Res. 2024;316(4):110.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1611_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s13555-024-01114-2","volume":"14","author":"S Molin","year":"2024","unstructured":"Molin S, Larsen LS, Joensson P, et al. Development and psychometric validation of a patient-reported outcome measure to assess the signs and symptoms of Chronic Hand Eczema: the Hand Eczema Symptom Diary (HESD). Dermatol Ther (Heidelb). 2024;14(3):643\u201369.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1611_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/bmjebm-2020-111573","volume":"27","author":"S Kluzek","year":"2022","unstructured":"Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27(3):153\u20135.","journal-title":"BMJ Evid Based Med"},{"key":"1611_CR17","doi-asserted-by":"publisher","first-page":"1408636","DOI":"10.3389\/fmed.2024.1408636","volume":"11","author":"D Almeida","year":"2024","unstructured":"Almeida D, Umuhire D, Gonzalez-Quevedo R, Antonio A, Burgos JG, Verpillat P, et al. Leveraging patient experience data to guide medicines development, regulation, access decisions and clinical care in the EU. Front Med (Lausanne). 2024;11:1408636.","journal-title":"Front Med (Lausanne)"},{"key":"1611_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-4-79","volume":"4","author":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research","year":"2006","unstructured":"US Department of Health and Human Services FDA Center for Drug Evaluation and Research, US Department of Health and Human Services FDA Center for Biologics Evaluation and Research, US Department of Health and Human Services FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006;4:79.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1611_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015;64(1):41\u201351.","journal-title":"Inflamm Res"},{"key":"1611_CR20","unstructured":"European Medicines Agency. Delgocitinib (Anzupgo\u00ae): Summary of Product Characteristics. European Medicines Agency (EMA); 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/anzupgo-epar-product-information_en.pdf. Accessed 15 Aug 2025."},{"key":"1611_CR21","unstructured":"ANZUPGO\u00ae (delgocitinib) cream [prescribing information]. 2025; Madison, New Jersey: LEO Pharma Inc. [updated 08\/2025]."},{"key":"1611_CR22","unstructured":"ANZUPGO\u00ae. Product Monograph. LEO Pharma Inc.; 2024b. Toronto, Ontario: LEO Pharma Inc. [updated 08\/2025]. https:\/\/pdf.hres.ca\/dpd_pm\/00081515.PDF. Accessed 15 Aug 2025."},{"issue":"10451","key":"1611_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","volume":"404","author":"R Bissonnette","year":"2024","unstructured":"Bissonnette R, Warren RB, Pinter A, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema (DELTA\u00a01 and DELTA\u00a02): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Lancet. 2024;404(10451):461\u201373.","journal-title":"Lancet"},{"issue":"4","key":"1611_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bjd.18295","volume":"182","author":"JAF Oosterhaven","year":"2020","unstructured":"Oosterhaven JAF, Schuttelaar MLA. Responsiveness and interpretability of the Hand Eczema Severity Index. Br J Dermatol. 2020;182(4):932\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1611_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40257-021-00669-6","volume":"23","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Hahn-Pedersen J, Bartlett C, Glanville J, Thyssen JP. Economic burden of Chronic Hand Eczema: a review. Am J Clin Dermatol. 2022;23(3):287\u2013300.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1611_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/bjd\/ljad156","volume":"189","author":"AN Voorberg","year":"2023","unstructured":"Voorberg AN, Kamphuis E, Christoffers WA, Schuttelaar MLA. Efficacy and safety of dupilumab in patients with severe Chronic Hand Eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase\u00a0IIb proof-of-concept study. Br J Dermatol. 2023;189(4):400\u20139.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1611_CR27","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1111\/jdv.16401","volume":"34","author":"HM Passlov","year":"2020","unstructured":"Passlov HM, Ponten A, Bjork J, et al. Hand strength and dexterity in individuals with hand eczema. J Eur Acad Dermatol Venereol. 2020;34(12):2856\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1611_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jamadermatol.2022.4211","volume":"158","author":"YA Leshem","year":"2022","unstructured":"Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema control and itch intensity in clinical practice: a consensus statement from the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) initiative. JAMA Dermatol. 2022;158(12):1429\u201335.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1611_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40271-019-00373-y","volume":"12","author":"A Barrett","year":"2019","unstructured":"Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and Chronic Hand Eczema in adults. Patient. 2019;12(5):445\u201359.","journal-title":"Patient"},{"issue":"1","key":"1611_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12955-021-01877-8","volume":"19","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, DeLozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1611_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1611_CR32","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/pm\/pnab110","volume":"22","author":"SM Nugent","year":"2021","unstructured":"Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Med. 2021;22(10):2235\u201341.","journal-title":"Pain Med"},{"issue":"6","key":"1611_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/cod.14066","volume":"86","author":"MJ Brands","year":"2022","unstructured":"Brands MJ, Loman L, Schuttelaar MLA. Exposure and work-related factors in subjects with hand eczema: data from a cross-sectional questionnaire within the Lifelines Cohort Study. Contact Dermat. 2022;86(6):493\u2013506.","journal-title":"Contact Dermat"},{"issue":"1","key":"1611_CR34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2025.03.008","volume":"93","author":"M Gooderham","year":"2025","unstructured":"Gooderham M, Molin S, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 52\u00a0weeks in adults with Chronic Hand Eczema: results of the phase\u00a03 open-label extension DELTA 3 trial following the DELTA\u00a01 and 2 trials. J Am Acad Dermatol. 2025;93(1):95\u2013103.","journal-title":"J Am Acad Dermatol"},{"issue":"10490","key":"1611_CR35","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gimenez-Arnau","year":"2025","unstructured":"Gimenez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe Chronic Hand Eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase\u00a03 trial. Lancet. 2025;405(10490):1676\u201388.","journal-title":"Lancet"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01611-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:33Z","timestamp":1772001633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01611-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01611-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrea Bauer has been a speaker, advisor, or investigator, and\/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Blueberry Therapeutics, Celldex, Centogene, Escient, Galderma, Genentech, Gilead, Incyte, Jasper, LEO Pharma A\/S, Lilly, L\u2019Or\u00e9al, Novartis, Pfizer, Sanofi, Regeneron, and Takeda. Marie-Louise Schuttelaar has been a consultant, advisory board member, investigator, and\/or speaker for AbbVie, Amgen, Eli Lilly, Galderma, LEO Pharma A\/S, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme. Keith Baranowski, Ursula Plohberger, and Laura S\u00f8rensen, are shareholders and employees of LEO Pharma A\/S. Margitta Worm reports grants and personal fees from AbbVie Deutschland, Allergopharma, Aimmune, ALK-Abello, Almirall S. A., Amgen GmbH, Biotest, Bristol-Myers Squibb GmbH & Co., DBV Technologies, KGaA, LEO Pharma A\/S, Lilly Deutschland, Mylan Germany, Novartis, Pfizer Deutschland GmbH, Regeneron Pharmaceuticals, and Sanofi Aventis, outside the submitted work and is past WAO co-chair of the anaphylaxis committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In the 10 countries where DELTA\u00a01 and DELTA\u00a02 were conducted, prior to screening of patients, the institutional review board or independent ethics committee at all centres approved the protocol, investigator\u2019s brochure, and any information provided to patients (Table\u00a0\n                      \n                      ). The trials were conducted according to the ethical principles of the Declaration of Helsinki. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}